Group 1 - The brain-computer interface (BCI) industry in China is entering a historic turning point in 2025, driven by a combination of policy, capital, and technological advancements [2][3][5] - The Chinese government has significantly strengthened its top-level design for the BCI industry, with the first implementation opinions issued by multiple ministries and its inclusion in the national "14th Five-Year Plan" [5][6] - The successful clinical trial of China's first invasive BCI marks a critical milestone, indicating significant progress in the field [6][7] Group 2 - Investment in the BCI sector is surging, with financing amounts increasing nearly fourfold year-on-year in 2025, reflecting a fundamental recovery in capital confidence [2][7][10] - The number of financing events in the BCI field has risen sharply, with 16 events totaling 983 million yuan in 2025, compared to only 6 events totaling 201 million yuan in 2024 [7][10] - The financing structure shows a trend towards earlier rounds of investment, with over 75% of events occurring in the angel to A rounds, indicating a growing willingness to support early-stage projects [10][12] Group 3 - The BCI industry is characterized by a unique "asymmetric advantage" in China, driven by large clinical needs, efficient transformation systems, and comprehensive policy support [2][21][22] - The medical application of BCI is recognized as a priority, with the healthcare sector accounting for 56% of the BCI market, while consumer applications are still developing [25][28] - The market for serious medical applications is projected to reach between 15 billion to 85 billion USD globally, while the consumer medical market could reach between 25 billion to 60 billion USD [25] Group 4 - The BCI industry faces challenges in proving medical value, establishing payment models, and addressing ethical issues, necessitating a pragmatic evolution from "spectacle" to "utility" [3][30][33] - The industry must overcome three interconnected challenges: clinical validation, building trust among medical professionals and patients, and demonstrating economic value to healthcare systems [33][36] - The commercial path for consumer-grade BCI products requires addressing issues of device invisibility, establishing essential demand, and achieving affordable pricing [34][35]

Market Strategy - The market opened lower but showed resilience, with the robotics sector gaining strength [5][7] - The overall A-share market saw a slight increase of 0.13%, closing at 6421.08 points, while the Shanghai Composite Index remained flat at 3965.12 points [7] - The hard technology sector, represented by the Sci-Tech 50 Index, rose by 1.01%, closing at 1359.87 points, indicating strong performance in this area [7] Industry Dynamics - JD Home Services launched a training base for elderly care services, investing 1 billion yuan over three years to develop high-standard elderly care courses [28][30] - From January to November 2025, motorcycle exports from China reached 16.67 million units, a year-on-year increase of 27.67%, with significant growth in exports to Latin America and Africa [31][32] - The online market for smart wearables saw a decline in sales, with November sales down 25.4% year-on-year, attributed to a lack of demand following earlier policy incentives [33][34] - The dairy product output from January to November 2025 was 26.85 million tons, a decrease of 1.2% year-on-year, reflecting challenges in the dairy sector [37][38] Company Updates - Haizhi Science (002653.SZ) received approval for clinical trials of its innovative drug HSK44459 for treating inflammatory bowel disease [41][42] - Aipeng Medical (300753.SZ) established a partnership for investment in brain-computer interface and neuroscience, with a fund size of 100 million yuan [43][44] - Changgao Electric (002452.SZ) announced that its subsidiaries won bids totaling 160.85 million yuan from the State Grid, which will positively impact future earnings [45][46]

证券代码：300753 证券简称：爱朋医疗 公告编号：2025-054 江苏爱朋医疗科技股份有限公司 关于与专业投资机构共同投资设立基金的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、与专业投资机构合作投资概述 为满足战略发展需求，充分借助专业投资机构的力量及资源优势，加快推动产业 布局优化，在不影响公司日常经营和发展、有效控制投资风险的前提下，江苏爱朋医 疗科技股份有限公司（以下简称"公司"）与江苏英掘私募基金管理有限公司、嘉兴 思麟创业投资合伙企业（有限合伙）共同投资设立了爱朋智链云脑（嘉兴）股权投资 合伙企业（有限合伙）（以下简称"基金"），该基金主要投资脑机接口、脑神经科 学、精神系统疾病及其他医疗健康领域。基金规模10,000万元，公司作为有限合伙人以 自有资金人民币4,970万元出资认购投资基金份额，出资比例为49.7%。具体内容详见公 司于2025年12月8日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于与专业投 资机构共同投资设立基金的公告》（公告编号：2025-053）。 二、基金进展情况 目前， ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth driven by favorable policies, technological advancements, and increased investment interest, as evidenced by the recent surge in stock prices of related companies in both Hong Kong and A-share markets [2][6][7]. Policy Developments - The National Medical Products Administration has included implantable brain-computer interface medical devices in the "Priority Approval List for High-end Medical Devices (2025 Edition)" [2]. - A joint initiative by seven ministries, including the Ministry of Industry and Information Technology, has set phased goals for the BCI industry by 2027 and 2030 [3]. - The "14th Five-Year Plan" emphasizes the BCI sector as a key area for fostering new economic growth [4]. - The National Healthcare Security Administration has introduced new pricing guidelines for invasive BCI procedures, facilitating reimbursement pathways [4]. Technological Advancements - Recent breakthroughs in BCI technology include the first domestically developed fully implanted, wireless BCI product by Brain Tiger Technology, which successfully completed its first clinical trial [5]. - The National Medical Products Administration has approved the world's first invasive BCI product for treating addiction-related mental disorders [5]. - Ongoing clinical trials and collaborations among research institutions and medical units are yielding significant progress in the field [5]. Market Insights - The BCI industry is entering a rapid commercialization phase, supported by policy backing, technological breakthroughs, and increased capital influx [5][6]. - The market for BCI is projected to be a nearly $10 billion opportunity globally, with domestic companies making strides in flexible electrodes and real-time Chinese language decoding [7]. - Investment interest in the BCI sector is rising, particularly in rehabilitation applications and non-invasive BCI technologies, as companies strategically position themselves for future growth [6][7].

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

知名机构近一周 上周共计12只个股获知名机ｵ 行业紧随其后; 个股上，领益 倍的溢价取得一家热管理公司 (66家) 和骄成超声（44家 股票名称 机构名称 记 博众精工 12 | 高教资产 | 昌红科技 | 12 | | --- | --- | --- | | | 亚太科技 | 12 | | 重阻 | 爱朋医疗 | 12 | | | 罗博特科 | 12 | | 星石投资 | 盐湖股份 | 12 | | 盘京投资 | 光庭信息 | 12 | | | 安集科技 | 12 | | | 骄成超声 | 12 | | 火 -レ 白 | | | *风险提示：股市有风险，入市需谨慎 *免责声明：文章内容仅供参考，不构成投资建议 ...

Group 1: Macro Insights - The US real estate market is currently in a "weak supply and demand" state, with expectations of a weak recovery by 2026 due to challenges in policy transmission and external risks [2] - Industrial profits in November continued to decline year-on-year, with only the midstream equipment sector showing stable growth, while upstream and downstream sectors weakened [3] - The A-share market has not shown clear signs of a bull market peak, indicating continued potential for market performance [4] Group 2: Market Strategies - The A-share market is expected to experience a spring rally supported by ongoing policy efforts and capital inflows, with a focus on growth and consumer sectors [5] - The REITs market has shown signs of price recovery after five weeks of decline, with notable returns compared to other asset classes [6] - Credit bond issuance increased by 15.42% week-on-week, indicating a positive trend in the credit market [7] Group 3: Industry Research - The green methanol sector is rapidly growing under the "carbon neutrality" initiative, with a focus on companies that have established a complete supply chain [10] - The engineering machinery industry is witnessing a recovery in domestic demand and accelerated overseas growth, with several key manufacturers recommended for investment [11] - Strategic metals are expected to see investment opportunities due to favorable supply-demand dynamics and resource nationalism [12] Group 4: Company Research - Sinopec Engineering's acquisition of the East China Pipeline Design Institute is expected to enhance its competitive edge in pipeline transportation [19] - China Oil Engineering has signed a $424 million EPC contract for a pipeline project in Kazakhstan, indicating its proactive expansion into overseas markets [20] - Jinhui Liquor is positioned to benefit from regional brand advantages and market expansion, with strong revenue and profit growth projections [21]

行 业 研 究 华福证券 机械设备 2025 年 12 月 28 日 太空脑机接口首试成功，深空神经探索启新程 投资要点： 突破技术壁垒，在轨验证创举 行 业 定 期 报 告 近日，西北工业大学牵头开发的两套太空专用小鼠无线植入式脑 机接口微系统，搭载"迪迩五号・中国科技城号"空间试验器成功升空 并进入预定轨道，目前运行稳定、数据正常回传。此次任务是国际首 次在太空环境下开展该类设备长期在轨离体验证，核心包含自研多通 道柔性微电极、神经信号采集芯片等关键部件，创新采用"动物舱" 与"独立舱"双室协同验证模式，攻克了太空复杂环境下信号采集、 长期稳定性等技术难题。 筑牢科研基础，赋能未来探索 该试验为后续无约束小动物在体在轨神经信号采集提供关键数据 与技术支撑，助力揭示太空对神经的影响机制、保障航天员脑健康。 其技术未来有望应用于月球/火星基地长期驻留任务，为人类深空探测 筑牢健康基石，同时推动中国植入式脑机接口技术迈入"太空时代"， 为脑科学太空探索及新质生产力发展注入强劲动力。 "十五五"重点赛道，脑机接口市场规模有望快速增长 根据 precedence research，2024 年全球脑机接口市场规模约 ...

Group 1 - The article discusses the rapid growth of the brain-machine interface industry, driven by both policy and technology, indicating a potential market worth billions [3][4]. - It highlights the integration of medical and consumer sectors, suggesting that companies like Xiangyu Medical and Weisi Medical may benefit from the implementation of medical insurance payments and increasing rehabilitation demands [4]. - The report emphasizes the strong commercial viability and high technological barriers of invasive and semi-invasive technology leaders such as Xinwei Medical and Brain Tiger Technology [4]. Group 2 - The insurance sector is experiencing a shift towards equity investments, with a record 9.3% of stock assets among five listed insurance companies, the highest in nearly a decade [9]. - Projections for the insurance industry indicate potential stock scale increments of 1.7 trillion, 2.4 trillion, and 3.1 trillion yuan under pessimistic, neutral, and optimistic scenarios for 2025-2027 [9]. - The article suggests that the upward trend in the equity market will significantly enhance investment returns for insurance companies [9]. Group 3 - The report on the real estate market indicates a 15.1% year-on-year decline in residential land transaction area, while the average transaction price per square meter increased by 9.4% [18]. - It notes that first-tier cities experienced a 29.5% increase in average transaction price, reflecting regional disparities in the real estate market [18]. - Recommendations include companies like Poly Development and China Merchants Shekou, as well as property service firms such as China Resources Mixc Life and Greentown Service, which are expected to benefit from long-term growth [18]. Group 4 - The article on high-end manufacturing exports highlights improvements in November due to the fading high base effect and strong seasonal replenishment demand from overseas [27]. - It suggests that new trade agreements between China and the U.S. may lead to a marginal recovery in exports to the U.S., with companies like Quan Feng Holdings being potential beneficiaries [27]. - The report also points out rapid growth in exports to emerging markets in Africa and Latin America, recommending companies like Anhui Heli [27]. Group 5 - The analysis of ABN products indicates that they still hold a yield advantage over some ordinary credit bonds, despite a lack of significant premium compared to other asset-backed securities [15]. - In a market with scarce high-yield assets, ABN products are positioned as a viable option for enhancing returns, while their valuation volatility is generally lower than that of ordinary credit bonds [15]. - This characteristic provides a degree of resilience against overall industry shocks, aiding in the optimization of investment portfolio stability [15].

Investment Rating - The report maintains an "Overweight" rating for the biomedical sector [4] Core Insights - The brain-computer interface (BCI) industry is at a critical stage of policy support, rapid technological iteration, and accelerated commercialization, with a global market approaching $10 billion [3][9] - The industry is driven by both policy and technology, with significant investments from major countries, including approximately $4.5 billion from the U.S. BRAIN Initiative and hundreds of billions in China [1][51] - The medical application of BCI technology is the most mature segment, focusing on neurorehabilitation, functional replacement, and disease treatment, with a dual growth curve emerging from medical and consumer applications [2][45] Summary by Sections Industry Overview - BCI is defined as a technology that creates a communication channel between the brain and external devices, enabling direct information exchange [16] - BCI can be categorized into invasive, semi-invasive, and non-invasive types, each with distinct applications in medical rehabilitation, consumer interaction, and military use [17][19] - The global BCI market is projected to grow from $1.2 billion in 2019 to approximately $7.63 billion by 2029, with a compound annual growth rate (CAGR) exceeding 13% [24] Policy Guidance - Major countries have launched BCI-related initiatives, with the U.S. and EU leading in funding and research efforts [52][53] - China's "Brain Plan" aims to enhance brain science and BCI technology, with significant funding expected in the coming years [54][57] Clinical Applications - The medical sector is the primary focus for BCI applications, with significant demand driven by conditions such as stroke and disabilities [45][48] - Clinical trials for BCI products are accelerating globally, with notable advancements in both invasive and non-invasive technologies [3][19] Industry Progress - The report highlights the competitive landscape, noting that while foreign companies like Neuralink and Synchron have a head start, domestic firms are making significant strides in key areas such as flexible electrodes and real-time language decoding [2][4][30] - The BCI industry is characterized by a complex supply chain, with upstream components like electrodes and chips, midstream product supply, and downstream applications across various sectors [30][33] Investment Recommendations - Investors are advised to focus on companies with strong technological barriers and clinical application capabilities, particularly in the medical sector, which is the most developed area for BCI commercialization [3][9] - Specific companies to watch include medical scene integrators and leaders in invasive/semi-invasive technologies, such as Xiangyu Medical, Weisi Medical, and Brain Tiger Technology [3][9]